SavedAdd your journal

Journals / Journal of Microbiology and Infectious Diseases / 2021 / Cilt: 11 - Sayı: 01

Frequency of Bacteremia due to Carbapenemase-producing Enterobacteriaceae in Pediatric Hematology-Oncology Can Be Reduced by Measures of Hospital Infection Control

Désirée CASELLİ
Pages
27–31
Publication Date
2021-03-15
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The overall rate of colonization was comparable between the two study periods: 0.50% (2016-2017) vs. 0.48% (2012-2013).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: The spread of carbapenemase-producing Enterobacteriaceae (CPE) is an emerging problem in children undergoing cancer-directed chemotherapy.
📊
Key Findings & Data:A previous Italian survey reported a threefold increase in CPE colonization rate and a fourfold increase of CPE bloodstream infections in a 2 year-observation time interval.
💡
Conclusion & Impact:Results: The overall rate of colonization was comparable between the two study periods: 0.50% (2016-2017) vs. 0.48% (2012-2013).
🔬Design:Survey & Empirical Study
📍Scope:2016-2017 Verileri
⚙️Variables:Carbapenemase-producing Enterobacteriaceae · children · oncology

Abstract

Objectives: The spread of carbapenemase-producing Enterobacteriaceae (CPE) is an emerging problem in children undergoing cancer-directed chemotherapy. A previous Italian survey reported a threefold increase in CPE colonization rate and a fourfold increase of CPE bloodstream infections in a 2 year-observation time interval. Methods: To assess the efficacy of the measures put in place to control this emergency, a second survey was performed in the years 2016-2017 and the results were compared. Results: The overall rate of colonization was comparable between the two study periods: 0.50% (2016-2017) vs. 0.48% (2012-2013). MDR/CPE bacteremia was now reported in 13 children from six centers. The rate of MDR/CPE bacteremia was 0.12 for 1,000 days of hospitalization (95% CI, 0.07-0.21) and compared favorably with that observed in the previous survey (0.42 for 1,000 days of hospitalization; 95% CI, 0.31-0.57; p

🔖

Cite This Article

CASELLİ, D. (2021). Frequency of Bacteremia due to Carbapenemase-producing Enterobacteriaceae in Pediatric Hematology-Oncology Can Be Reduced by Measures of Hospital Infection Control. Journal of Microbiology and Infectious Diseases, Cilt: 11 - Sayı: 01, 27–31. https://ajindex.com/articles/111279

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Tassios GL, Daikos LS, Tzouvelekis A, Markogiannakis M, Psichogiou PT. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25:682–707
  2. Queenan AM, Bush K. Carbapenemases: the versatile b-lactamases. Clin Microbiol Rev 2007; 20:440–58
  3. Tsioutis C, Eichel VM, Mutters NT. Transmission of Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae: the role of infection control. J Antimicrob Chemother. 2021; 76 (Supplement 1):i4-i11
  4. Caselli D, Cesaro S, Fagioli F, et al. Incidence of colonization and bloodstream infection with carbapenem-resistant Enterobacteriaceae in children receiving antineoplastic chemotherapy in Italy. Infect Dis 2016; 48:152-5
  5. Iacchini S, Sabbatucci M, Gagliotti C, et al. Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017. Euro Surveill. 2019;24(5):1800159
  6. Magiorakos AP, Burns K, Rodríguez Baño J. et al. Infection prevention and control measures and tools for the prevention of entry of carbapenem-resistant Enterobacteriaceae into healthcare settings: guidance from the European Centre for Disease Prevention and Control. Antimicrob Resist Infect Control 6, 113 (2017)
  7. Arendrup MC, Hope W, Howard SJ. EUCAST Definitive Document E.Def 9.2 Method for the Determination of Broth Dilution Minimum Inhibitory Concentrations of Antifungal Agents for Conidia Forming Moulds; EUCAST: Basel, Switzerland, 2014
  8. Clinical Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd ed.; CLSI document M38-A2; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2008
  9. Martelius T, Jalava J, Kärki T, et al. Nosocomial bloodstream infections caused by Escherichia coli and Klebsiella pneumoniae resistant to third-generation cephalosporins, Finland, 1999-2013: Trends, patient characteristics and mortality. Infect Dis 2016; 48:229-34
  10. Marín M, Gudiol C, Garcia-Vidal C, Ardanuy C, Carratalà J. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center. Medicine (Baltimore). 2014;93(3):143-9
  11. Avendano E, Raman G, Chan J, McCann E. Burden of carbapenem non-susceptible infections in high-risk patients: systematic literature review and meta-analysis. Antimicrob Resist Infect Co